Five papers extend the list of cancers that respond to therapies that restore antitumour immunity by blocking the PD-1 pathway, and characterize those patients who respond best. See Letters p.558, p.563, p.568, p.572 & p.577
- Jedd D. Wolchok
- Timothy A. Chan